Patent intelligence · US
US 7288263
Compositions and methods for treatment of skin discoloration
Compositions and methods for treatment of skin discoloration
Patent details — US 7288263
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 30, 2007
- Expiration
- Oct 25, 2027
- Applicant
- Evera Laboratories, LLC
- Claims
- 24
- CPC classes
- A61K, A61K8/41, A61K8/415, A61K8/4926
Quick answer
US 7288263 (Compositions and methods for treatment of skin discoloration) is held by Evera Laboratories, LLC. Status: granted. Granted Oct 30, 2007. Expires Oct 25, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Evera Laboratories, LLC
- Grant date
- Expiration
- Claims
- 24
- CPC classes
- A61K, A61K8/41, A61K8/415, A61K8/4926, A61K8/4946
More from Evera Laboratories, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12403164
Lentiviral vector formulations
granted -
US 12403183
Factor VIII polypeptide formulations
granted -
US 12391750
Anti-C1S antibodies and methods of use thereof
granted -
US 12371747
Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
granted -
US 12364774
Nucleic acid molecules and uses thereof for non-viral gene therapy
granted -
US 12268688
Compositions and methods of use for modified release minoxidil
granted -
US 12257288
Methods of inducing immune tolerance to clotting factors
granted -
US 12240917
Anti-complement C1s antibodies and uses thereof
granted
Frequently asked questions
What is US patent 7288263?
US 7288263 (Compositions and methods for treatment of skin discoloration) is held by Evera Laboratories, LLC. Status: granted. Granted Oct 30, 2007. Expires Oct 25, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7288263?
Evera Laboratories, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 140 pharmaceutical patents for this assignee.
When does US 7288263 expire?
Our index shows an expiration date of Oct 25, 2027 (1 year from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.